Drugs / Runcaciguat
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04820621 | Apr → Jul 2021 | chronic kidney disease | Bayer | Terminated | No outcome recorded Stop: Business |
| Phase 22 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT04722991 | Mar 2021 → Mar 2024 | severe nonproliferative diabetic retinopathy | Bayer | Completed | Missed primary |
| Phase 2 | NCT04507061 | Sep 2020 → Mar 2022 | chronic kidney disease | Bayer | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | runcaciguat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04507061 ↗ |
| Known as | BAY1101042 | “Runcaciguat (BAY 1101042) is a novel, potent, and selective sGC activator” PMID 37686032 ↗ Aug 2023 |
| Action | Activate | “Runcaciguat, an sGC activator, activates heme-free sGC, restoring cGMP production.” PMID 39656628 ↗ May 2025 |
| Modality | Small molecule | — CHEMBL4650322 ↗ |
| Route | Oral | “Titrated dose of active dose 1, dose 2, dose 3, dose 4 of runcaciguat will be administered orally once a day.” NCT04507061 ↗ |